

**Virginia's Department of Medical Assistance Services  
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, Virginia 23219*

**Thursday, September 21, 2023 - 10:00 a.m.**

**Welcome and Comments from DMAS' Director**

**Cheryl Roberts, JD Medicaid Director**

**Call to Order**

**Lisa Price Stevens MD, CMO, Chair**

**Drug Utilization Review (DUR) Board Update**

**Rachel Cain, PharmD**

**Approval of Minutes from March 23, 2023, Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

**Old business**

- P&T Bylaws

**Phase II – New Drug Review (Therapeutic Class)**

**Brand Drugs**

- Vowst™ (Antibiotics, GI)
- Inpefa™ (Hypoglycemics, SGLT2) (Closed Class)
- Brixadi™ (Opiate Dependence Treatments) (Closed Class)

**Biosimilar for Humira**

- Adalimumab-Adaz (Cytokine and CAM Antagonists) (Closed Class)
- Adalimumab-Fkjp Pen
- Cyltezo®
- Hadlima™
- Hulio®
- Hyrimoz®
- Idacio®
- Yuflyma®
- Yusimry™

**Generics Drugs and New Dosage Forms**

- Vancomycin 25 Mg/ML Solution generic for Firvanq Kit (Antibiotics, GI)

**PDL Phase I – Annual Review -**

**Antivirals**

- Hepatitis C Agents (Closed Class)
- HIV (Closed Class)

**Blood Modifiers**

- Bile Acid Salts
- Hemophilia Treatment (Closed Class)

### **Cardiac Medications**

- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Lipotropics, Statins
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)

### **Central Nervous System**

- Antidepressants, Other
- Antidepressants, SSRI
- Antipsychotics (includes oral and long acting injectables) (Closed Class)
- Movement Disorders (Closed Class)
- Sedative Hypnotics

### **Dermatitis**

- Immunomodulators, Atopic Dermatitis (Closed Class)

### **Endocrine & Metabolic Agents Oral**

- Growth Hormones (Closed Class)
- HAE Treatments
- Weight Management Agents (Closed Class)

### **Gastrointestinal**

- GI Motility, Chronic
- Proton Pump Inhibitors

### **Ophthalmic**

- Ophthalmic, Anti-Inflammatory/Immunomodulator (Closed Class)
- Ophthalmic, Glaucoma

### **Respiratory**

- Anti-Allergens, Oral

### **Classes reviewed by DMAS with no significant changes:**

#### **Antibiotics/Anti-Infectives**

- Antibiotics, Vaginal

#### **Blood Modifiers**

- Phosphate Binders
- Sickle Cell Anemia Treatments (Closed Class)

#### **Cardiac Medications**

- Angiotensin Modulator Combinations
- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Antihypertensives, Sympatholytics
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)

#### **Central Nervous System**

- Anticonvulsants (Closed Class)

**Dermatitis**

- Steroids, Topical

**Endocrine & Metabolic Agents Oral**

- Glucocorticoids, Oral
- Glucagon Agents (**Closed Class**)
- Progestins for Cachexia

**Gastrointestinal**

- Antiemetic/Antivertigo Agents
- H. pylori Agents
- Histamine II Receptor Antagonists
- Ulcerative Colitis

**Genitourinary**

- Bladder Relaxants
- BPH Agents

**Ophthalmic**

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)

**Respiratory**

- Antibiotics, Inhaled (**Closed Class**)
- Antihistamines, Minimally Sedating
- Bronchodilators, Beta Agonist
  - a. Bronchodilators, Long-Acting Beta Adrenergics
  - b. Bronchodilators, Short Acting Beta Adrenergics
- COPD Agents (**Closed Class**)
- Cough & Cold Agents (*Legend*)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*) (**Closed Class**)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)
- Leukotriene Modifiers

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**PDL Recommendations and Vote**

**P&T Committee Members**

**Criteria Discussion of Phase II New Drugs\***

**P&T Committee Members**

**Criteria Discussion of PDL Phase I Drug Classes\***

**P&T Committee Members**

**Next Meeting - tentatively scheduled for March 21, 2024.**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Oral Presentations:** The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL Phase I drugs in classes in which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – September 2022 to present.
- New Drugs in PDL Phase I or II Drug Classes – September 2021 to present.

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on Thursday, August 24, 2023.

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by 5 p.m. EST on Thursday, August 24, 2023.

DRAFT